Short communicationAnti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach
References (12)
- et al.
IL-5 modulates eosinophil accumulation in allergic guinea pig lung
J. Allergy Clin. Immunol.
(1991) Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. Patterns of response in relation to immunization regimen
Allergy
(1980)- et al.
Inhibition of Aeroallergen-Induced Immediate Asthmatic Response and Late Phase Bronchoalveolar Eosinophilia by Azelastine in Actively Sensitized Guinea Pigs
Am. Rev. Respir. Dis.
(1990) - et al.
Therapeutic approach for the evaluation of antiasthma compounds in allergic bronchial inflammation in guinea pigs
Am. Rev. Respir. Dis.
(1991) - et al.
CD4 T-lymphocyte activation in acute severe asthma - relationship to disease severity and atopic status
Am. Rev. Respir. Dis.
(1990) A Unopette for eosinophil counts
Am. J. Clin. Pathol.
(1970)
Cited by (113)
Proinflammatory Pathways in the Pathogenesis of Asthma
2019, Clinics in Chest MedicineCitation Excerpt :One-time IL-5 challenge of guinea pig airways induced a dose-dependent significant increase in the number of eosinophils, neutrophils, and epithelial cells in BAL fluid 24 hours after administration, and this cell recruitment was inhibited by corticosteroids and ketotifen.52 In a guinea pig model of acute allergic inflammation induced by ovalbumin sensitization and challenge, anti–IL-5 antibody treatment significantly reduced BAL eosinophils 4 hours after allergen challenge.53 In a guinea pig model of chronic ovalbumin challenge, anti–IL-5 treatment not only significantly reduced BAL eosinophilia, but also histamine-induced airway reactivity, whereas the number of airway neutrophils was not affected.54
Using guinea pigs in studies relevant to asthma and COPD
2008, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :The late phase physiologic response in human subjects is largely inhibited by a combination of histamine and leukotriene receptor antagonists and is associated with an influx of eosinophils into the airway wall and air spaces [124,135,143,155,158]. Comparable results have been reported in studies of the late response in guinea pigs [25–27,86,120,121,141,145,155,162,192,195–197,201,204]. Therapeutics including steroids and anti-IL-5 prevent the late phase eosinophilia evoked by allergen challenge in both species [141,143,145,154,158,162,192,194–197,204].
Characterization of a palindromic enhancer element in the promoters of IL4, IL5, and IL13 cytokine genes
2003, Journal of Allergy and Clinical ImmunologyThe effects of IL-5 on airway physiology and inflammation in rats
2003, Journal of Allergy and Clinical ImmunologyAsthma: Future directions
2002, Medical Clinics of North America